BCL2 and acute lymphoblastic leukemia: Two major BCL-2 inhibitors, venetoclax and navitoclax, have emerged in recent years as effective novel therapeutic approaches across several different hematological malignancies including ALL, and new-generation BCL-2 inhibitors molecules are under preclinical and clinical investigation (Table 1).